Figure 3

Amuvatinib treatment decreases phospho-MET protein in freshly obtained CD138+ cells. (A) Flow cytometric analysis of the levels of p-MET (Tyr1234/Tyr1235) in CD138+ cells from patients 6 and 8 after 24 h treatment with (thick black line) or without (gray shaded peak) 25 μM amuvatinib. (B) p-MET and total MET were quantified in untreated (white bars) and 25 μM amuvatinib treated cells (hashed bars) from panel (A) along with total MET levels in untreated (black bars) and 25 μM amuvatinib treated cells (diagonal bars). (C) Plot represents the levels of p-MET (Tyr1234/Tyr1235) in CD138– cells from patient 8 24 h after treatment with (thick black line) or without (gray shaded peak) 25 μM amuvatinib, and secondary only control (dashed line).